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Abstract
Troglitazone is an oral insulin-sensitizing drug used to treat patients with type 2 diabetes. A major feature of this
hyperglycemic state is the presence of increased rates of hepatic gluconeogenesis, which troglitazone is able to ameliorate. In
this study, we examined the molecular basis for this property of troglitazone by exploring the effects of this compound on the
expression of the two genes encoding the major regulatory enzymes of gluconeogenesis, phosphoenolpyruvate carboxykinase
(PEPCK) and glucose-6-phosphatase (G6Pase) in primary cultures of rat hepatocytes. Insulin is able to inhibit expression of
both of these genes, which was verified in our model system. Troglitazone significantly reduced mRNA levels of PEPCK and
G6Pase in rat hepatocytes isolated from normal and Zucker^diabetic rats, but to a lesser extent than that observed with
insulin. Interestingly, troglitazone was unable to reduce cAMP-induced levels of PEPCK mRNA, suggesting that the
molecular mechanism whereby troglitazone exerted its effects on gene expression differed from that of insulin. This was
further supported by the observation that troglitazone was able to reduce PEPCK mRNA levels in the presence of the insulin
signaling pathway inhibitors wortmannin, rapamycin, and PD98059. These results indicate that troglitazone can regulate the
expression of specific genes in an insulin-independent manner, and that genes encoding gluconeogenic enzymes are targets for
the inhibitory effects of this drug. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Type 2 diabetes is characterized by reduced insulin
sensitivity, resulting in decreased glucose metabolism
and increased hepatic glucose output, as well as a
failure by the pancreas to compensate for this insulin
resistance due to defects in glucose-stimulated insulin
secretion (reviewed in [1]). The resulting hyperglyce-
mia, and the inability of many patients to adequately
regulate their blood glucose levels, is what eventually
leads to the debilitating and sometimes fatal aspects
of this disease including cardiomyopathy, retino-
pathy, nephropathy, and neuropathy. It is now well
recognized that regulation of blood glucose levels in
these patients should be the primary concern upon
which their treatment is based [2].
Glucose homeostasis involves the coordinated reg-
ulation of several metabolic pathways including glu-
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coneogenesis. Phosphoenolpyruvate carboxykinase
(PEPCK) is generally considered to be the rate-limit-
ing enzyme of this pathway [3], although glucose-6-
phosphatase (G6Pase) is also a pace-setting enzyme
[4]. Therefore, it is not surprising that the activity of
PEPCK is elevated in nearly all models of diabetes
examined to date, regardless of whether they are of
chemical or genetic origin [5^8]. Indeed, an type 2
diabetes-like syndrome can be produced in rodents
simply by over-expressing the PEPCK gene [9]. This
observation emphasizes the role that PEPCK plays in
the complications of, and in some cases perhaps the
etiology of, diabetes. An interesting feature of this
enzyme that distinguishes it from most other rate-
limiting enzymes is that it has no known allosteric
modi¢ers [10]. Instead, regulation of its activity is
exerted primarily through control of gene expression
[11]. It should be noted that two isoforms of PEPCK
exist. The mitochondrial form is constitutively ex-
pressed, while the cytosolic form is tightly regulated
by multiple hormones at the level of transcription,
and is the form of this enzyme which is elevated in
diabetes [11].
A number of oral hypoglycemic or anti-hypergly-
cemia agents have been developed for the treatment
of type 2 diabetes, with di¡ering mechanisms of ac-
tion. The most recently developed group of com-
pounds, which are structurally unrelated to sulfonyl-
ureas and biguanides, are the thiazolidinediones of
which troglitazone is the member currently in clinical
use [12]. Troglitazone improves hepatic, adipose, and
skeletal muscle insulin resistance and ameliorates hy-
perinsulinemia in both obese^non-diabetic patients
and those with type 2 diabetes (reviewed in [12,13]).
It is e¡ective in lowering serum triglycerides and rais-
ing HDL cholesterol [13]. Of most importance, how-
ever, is its ability to lower blood glucose levels which
it achieves, at least in part, by inhibiting hepatic
gluconeogenesis [14,15].
Since troglitazone is a relatively new drug, infor-
mation regarding its molecular mechanism of action
is sparse. While it is clear that it acts to potentiate
the action of insulin, there is also evidence that it has
direct insulin-like e¡ects in speci¢c tissues, including
e¡ects on gene expression [16,17]. At least some of
these e¡ects result from direct binding of thiazolidi-
nediones to the Q-isoform of the peroxisome prolifer-
ator-activated receptors (PPARs) [18,19]. Given that
the regulation of PEPCK and G6Pase activity is pri-
marily determined at the level of transcription, and
that one of the physiological e¡ects of thiazolidine-
diones is to decrease hepatic gluconeogenesis [14,15],
we examined in the present study the e¡ect of trogli-
tazone on the expression of genes encoding these two
gluconeogenic enzymes.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed essential medium (DMEM)
and fetal bovine serum (FBS) were obtained from
Gibco-BRL (Burlington, Ont., Canada). Troglita-
zone and PD98059 were gifts from Parke-Davis
(Ann Arbor, MI, USA), and metformin was ob-
tained from Nordic (Kirkland, Ont., Canada). Wort-
mannin was purchased from Biomol (Plymouth
Meeting, PA, USA), and rapamycin was from ICN
Pharmaceuticals (Costa Mesa, CA, USA). Insulin,
salmon sperm DNA, N6,2P-O-dibutyryladenosine
3P,5P-cyclic monophosphate (db-cAMP), and colla-
gen were purchased from Sigma-Aldrich (Oakville,
Ont., Canada). Collagenase was obtained from Wor-
thington (Freehold, NJ, USA). Restriction endonu-
cleases were from Promega (Madison, Wisconsin,
USA). Klenow enzyme and TriZol reagent were ac-
quired from Gibco-BRL. Chemstrips bG and 5L
(blood and urine glucose analysis, respectively) and
Random Priming hexanucleotide mix were from
Boehringer-Mannheim (Laval, Que., Canada). Gen-
escreen Plus membranes and [K-32P]dCTP (3000 Ci/
mmol) were purchased from DuPont-New England
Nuclear (Boston, MA, USA). All other molecular
biology grade reagents were obtained from Fisher
Scienti¢c (Nepean, Ont., Canada) and BDH (Toron-
to, Ont., Canada).
2.2. Animals and cell culture
Principles of laboratory animal care were followed,
and all protocols were approved by the University of
Saskatchewan Committee on Animal Care and Sup-
ply. Male Sprague^Dawley (150^200 g), and BB/
Zucker obese^diabetic (BB/ZDP) rats were obtained
from Charles River (St. Constant, Que., Canada)
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and the Department of Pathology, University of
Massachusetts, respectively. The animals were fed
ad libitum and kept under a 12-h light^dark cycle.
BB/ZDP rats used in the experiments had blood glu-
cose levels of s 17 mM and glucosuria of s 14 mM.
Aged-matched BB/ZDR (diabetic resistant) control
rats were harvested at the same time as the BB/
ZDP rats. Hepatocytes were isolated by the collage-
nase perfusion method described by Cascales et al.
[20]. Cell viability was determined by the Trypan
blue exclusion method and was typically s 90%.
Cells were placed into collagen-coated 100-mm cul-
ture dishes at a concentration of one to two million
cells per plate and incubated in a humidi¢ed atmos-
phere (5% CO2) at 37‡C. After 1 h, cells were
checked for attachment and the medium replaced
with 10% FBS/DMEM. Following a 4 h incubation
period, the medium was replaced with serum-free
DMEM containing 0.2% bovine serum albumin
and incubated for an additional 8 h. Cells were
then treated with hormones and/or modulators for
8 h as described in the ¢gure legends. The vehicle
for troglitazone was dimethylsulfoxide, and that for
metformin was phosphate-bu¡ered saline.
2.3. Plasmids and probes
The PEPCK cDNA was released from the plasmid
pPCK10 [21] by PstI digestion. The cDNA for the
catalytic subunit of G6Pase was released from BS/
G6Pase/7.1 [22] by HindIII/BamHI digestion. The
cDNA insert for ribosomal phosphoprotein PO
(RPPO), used as a control probe in the Northern
experiments, was excised from p36B4 [23] by PstI
digestion. The cDNA probes were prepared by the
random priming method, using [K-32P]dCTP as the
radiolabeled substrate, as per instructions supplied
with the hexanucleotide mixture (Boehringer Mann-
heim).
6
Fig. 1. Troglitazone treatment of hepatocytes leads to a reduc-
tion in PEPCK and G6Pase mRNA levels. Primary cultures of
rat hepatocytes were treated for 8 h with either 500 WM db-
cAMP, 10 nM insulin, 100 WM troglitazone, 250 WM metfor-
min, or various combinations thereof. Control plates were
treated with DMSO vehicle. Cells were then harvested and total
cellular RNA was isolated. Northern analysis was performed
on 20 Wg of RNA, and the initial hybridization was performed
using 10U106 cpm of a PEPCK cDNA probe, following by
subsequent stripping and re-probing with cDNA probes for
G6Pase and RPPO. The latter probe served as a control for as-
sessment of equivalent RNA loading. Shows a representative
Northern blot from a single experiment. (B) Summary of
PEPCK Northern blot data (means þ S.E.) from three experi-
ments; only the most relevant treatments are shown. The aver-
age densitometric value for the levels in control (untreated) hep-
atocytes was arbitrarily set at 1.0. Ins, insulin; Trog,
troglitazone; Met, metformin.
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2.4. RNA extraction and Northern blot analysis
TriZol reagent was used to prepare RNA samples
according to the manufacturer’s instructions. For
Northern analysis, 20 Wg RNA were resolved on
1% agarose-formaldehyde gels and transferred onto
membranes by capillary elution. Membranes were
UV-crosslinked at 254 nm (1200 WW/cm2, Strata-
linker 1800, Stratagene, La Jolla, CA, USA) to facil-
itate subsequent stripping and reprobing. The mem-
branes were hybridized in 5USSPE (0.75 M NaCl,
50 mM NaH2PO4, 5 mM EDTA, pH 7.4), 0.5% so-
dium dodecyl sulfate, 5UDenhardt’s solution, 10%
dextran sulfate containing 100 Wg/ml denatured sal-
mon sperm DNA for 16^20 h at 65‡C in a forced air
rotary hybridization oven (TurboSpeed oven, Bio/
Can Scienti¢c, Mississauga, Ont., Canada). After hy-
bridization, membranes were washed with 2USSPE,
0.1% SDS at room temperature, followed by 1U
SSPE, 0.1% SDS at 65‡C. The probed membranes
were exposed to X-ray ¢lm at 380‡C and autoradio-
graphs were quanti¢ed using a laser densitometer
(LKB 2002 Ultrascan, Bromma, Sweden). Mem-
branes were stripped and re-probed as per the man-
ufacturer’s instructions.
3. Results
We set out to determine whether troglitazone’s
ability to inhibit hepatic gluconeogenesis might be
linked to an inhibition of the expression of genes
encoding enzymes which regulate the rate of gluco-
neogenesis. PEPCK is considered to be a major pace-
setting enzyme for this metabolic pathway, and alter-
ations in PEPCK mRNA levels have been shown to
accurately re£ect changes in PEPCK activity as well
as rates of gluconeogenesis (reviewed in [24]). As
shown in Fig. 1A,B, we observed that treatment of
hepatocytes with 100 WM troglitazone for 8 h de-
creased PEPCK mRNA levels by approximately
50% (compare Control with Trog). Insulin had a
more pronounced inhibitory e¡ect on PEPCK
mRNA levels compared with troglitazone. For com-
parison purposes, we examined the e¡ect of metfor-
min, another drug used in the treatment of type 2
diabetes, for its ability to inhibit PEPCK gene ex-
pression. However, metformin, when used at concen-
trations which inhibit hepatic gluconeogenesis [25],
had no signi¢cant e¡ect on PEPCK mRNA levels
(Fig. 1A). The concentration of troglitazone used in
the study shown in Fig. 1 was selected based upon
the dose^response experiment shown in Fig. 2, where
100 Wmol/l consistently produced an inhibitory e¡ect.
The speci¢city of this response produced by the rel-
atively high concentrations of troglitazone was evi-
dent not only from the lack of e¡ect on RPPO
mRNA levels, but also from the observation that
mRNA and protein levels of PPARQ are actually
induced in a dose-dependent manner by troglitazone
Fig. 2. Dose^response determination of the troglitazone e¡ect
on PEPCK gene expression. Primary cultures of rat hepatocytes
were treated for 8 h with the indicated concentrations of trogli-
tazone, and then RNA was isolated from the cells. (A) A repre-
sentative Northern blot from a single experiment. (B) Summary
of data (means þ S.E.) from three experiments. The analysis was
performed as described in the legend to Fig. 1.
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up to 200 WM in isolated hepatocytes (G.F. Davies,
R.L. Khandelwal, and W.J. Roesler, unpublished ob-
servations).
The transcription rate of the PEPCK gene is
stimulated by cAMP, a response which can be par-
tially or wholly reversed by insulin [26]. Since both
insulin and troglitazone inhibited basal PEPCK
mRNA levels, we were interested to see if troglita-
zone had any e¡ect on cAMP-induced levels of
PEPCK mRNA. As shown in Fig. 1A,B, db-cAMP
treatment of hepatocytes led to an increase in
PEPCK mRNA, and insulin treatment partially re-
versed this response. However, troglitazone had no
e¡ect on db-cAMP induced levels of PEPCK
mRNA, suggesting that insulin and troglitazone in-
hibit PEPCK gene expression via di¡erent mecha-
nisms. It should also be noted that neither metformin
nor a combination of troglitazone and metformin
had any inhibitory e¡ect on cAMP-induced mRNA
levels.
G6Pase is another enzyme which is considered to
catalyze a rate-limiting step in gluconeogenesis, given
its position as the terminal enzyme in the pathway
[4]. Since the regulation of the expression of the
G6Pase gene is in some respects similar to that of
PEPCK [22], we decided to examine the e¡ect of
troglitazone on its mRNA levels. Insulin had a
strong repressive e¡ect on the abundance of
G6Pase mRNA (Fig. 1A), consistent with previous
observations [22]. Troglitazone also led to an ap-
proximately 50% inhibition of basal G6Pase expres-
sion. In this particular experiment, metformin had an
inhibitory e¡ect, although this was not a consistent
observation in the several experiments we performed
(data not shown). Also evident from Fig. 1A is that
while db-cAMP had no detectable ability to increase
Fig. 3. Comparison of the time course of the troglitazone and insulin e¡ect on PEPCK mRNA levels. Primary cultures of rat hepato-
cytes were treated with either 100 WM troglitazone or 10 nM insulin for the indicated time, and then RNA isolated. (A) A representa-
tive Northern blot from a single experiment. (B) Summary of data (means þ S.E.) from three experiments, with the level of mRNA at
zero time being assigned an arbitrary value of 1.0. The analysis was performed as described in the legend to Fig. 1.
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G6Pase mRNA, db-cAMP did prevent the troglita-
zone-mediated decrease in mRNA levels.
Fig. 3A,B shows the time-course e¡ects of trogli-
tazone and insulin on PEPCK mRNA levels in iso-
lated hepatocytes. Inhibition by either treatment was
detectable by 30 min. However, troglitazone pro-
duced a more rapid decline in PEPCK mRNA com-
pared with insulin, with almost undetectable levels by
2 h. At 8 h, there is a reappearance of PEPCK tran-
script; this is consistent with the only partial inhib-
ition of PEPCK gene expression by troglitazone
which we observed in 8-h incubation experiments
(Fig. 1B).
Since troglitazone is e¡ective in lowering blood
glucose levels and hepatic glucose output in type 2
diabetes, we examined whether it could reduce the
expression of PEPCK and G6Pase genes in hepato-
cytes isolated from the Zucker diabetic^obese rat,
which are known to be insulin-resistant [27]. As
shown in Fig. 4A,B, the basal levels of both PEPCK
and G6Pase mRNA are elevated in these diabetic
rats compared with their non-diabetic litter mates.
In both non-diabetic and diabetic rats, troglitazone
was able to reduce the expression of the two gluco-
neogenic genes. It should be noted that despite the
insulin-resistant phenotype, insulin was e¡ective in
reducing PEPCK and G6Pase mRNA levels in hep-
atocytes prepared from these type 2 diabetic^obese
rats (data not shown).
The data above suggested that troglitazone inhibits
expression of the PEPCK gene by an insulin-inde-
pendent mechanism, based upon the fact that there
was no insulin present in the de¢ned culture medium,
and that insulin, but not troglitazone, was able to
inhibit cAMP-induction of PEPCK gene expression.
To test this hypothesis further, we examined the in-
hibitory e¡ect of troglitazone in the presence of in-
sulin signaling pathway inhibitors. The inhibitors
used were wortmannin, which inhibits phosphatidyl-
inositol kinase; PD98059, which binds to and inhib-
its MEK; and rapamycin, which is an inhibitor of
p70s6k. As can be observed in Fig. 5A,B, neither
PD98059 nor rapamycin alone had any e¡ect on
PEPCK mRNA levels, while wortmannin treatment
led to a reduction in mRNA. None of the three in-
hibitors tested were able to prevent the reduction in
PEPCK mRNA mediated by troglitazone (Fig. 5).
Consistent with previous observations [28], wortman-
Fig. 4. Troglitazone reduces PEPCK and G6Pase mRNA levels
in hepatocytes from Zucker diabetic^obese rats. Northern anal-
ysis was performed on RNA isolated from hepatocytes from
Zucker diabetic^obese rats and non-diabetic littermates as de-
scribed in the legend to Fig. 1. Troglitazone treatment (100
WM) was for 8 h. (A) A representative Northern blot from a
single experiment. (B) Summary of data (means þ S.E.) from
three experiments, with the level of PEPCK or G6Pase mRNA
in untreated hepatocytes from diabetic rats assigned an arbi-
trary value of 1.0. Control plates were treated with DMSO ve-
hicle only. ZDF, Zucker diabetic^obese hepatocytes; ND, non-
diabetic hepatocytes.
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nin was able to partially inhibit the insulin-mediated
reduction in PEPCK mRNA (Fig. 6A,B). It should
be noted that PD98059 and rapamycin have been
shown previously not to block insulin’s ability to
inhibit PEPCK gene expression [28,29].
4. Discussion
Troglitazone is a relatively new therapeutic agent
used in the treatment of type 2 diabetes. It is an
insulin sensitizer, and has been shown to be able to
prevent or reverse several physiological alterations
which are characteristic of insulin resistance [12,13].
One of the major physiological e¡ects it has is to
lower blood glucose, apparently by both inhibiting
hepatic gluconeogenesis [14,15,26] and increasing
glucose utilization [14,30]. While some of these ef-
fects result from an improvement in insulin sensitiv-
ity, a number of studies, including the present one,
have shown that troglitazone also has direct, insuli-
Fig. 6. E¡ect of wortmannin on insulin-mediated inhibition of
PEPCK gene expression. Northern analysis was performed on
RNA isolated from hepatocytes from male Sprague^Dawley
rats as described in the legend to Fig. 1. Hepatocytes were pre-
treated with 500 nM wortmannin for 30 min prior to the addi-
tion of 10 nM insulin. (A) A representative Northern blot from
a single experiment. (B) Summary of data (means þ S.E.) from
three experiments. Ins, insulin; Wort, wortmannin.
Fig. 5. E¡ect of insulin signaling pathway inhibitors on troglita-
zone-mediated inhibition of PEPCK mRNA levels. Northern
analysis was performed on RNA isolated from hepatocytes
from male Sprague^Dawley rats as described in the legend to
Fig. 1. Hepatocytes were pretreated with wortmannin (500 nM),
PD98059 (20 WM) or rapamycin (200 nM) for 30 min prior to
the addition of 100 WM troglitazone to the media. (A) A repre-
sentative Northern blot from a single experiment. (B) Summary
of data (means þ S.E.) from three experiments. Trog, troglita-
zone; Wort, wortmannin; PD, PD98059; Rap, rapamycin.
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nomimetic properties, including both activation and
inhibition of gene expression [14,16,17,31^33].
The molecular details whereby troglitazone inhib-
its hepatic gluconeogenesis have not been extensively
studied. Troglitazone was shown to decrease the ac-
tivity of hepatic fructose-1,6-bisphosphatase in
treated db/db mice [15]. It has also been postulated
that troglitazone may decrease cofactor (acetyl CoA,
NADH, ATP) availability which could lead to de-
creased rates of gluconeogenesis [34]. In the present
study, we suggest an additional mechanism of action
for troglitazone, that being to rapidly inhibit the ex-
pression of genes encoding two rate-limiting gluco-
neogenic enzymes, PEPCK and G6Pase. This e¡ect
was insulin-independent, observable in the absence of
insulin in the culture medium and insensitive to in-
sulin-signaling inhibitors. These data suggest that in-
hibition of PEPCK gene transcription can occur
through at least two di¡erent signaling mechanisms,
one being a wortmannin-sensitive insulin-dependent
pathway [28] and another which is insulin-independ-
ent.
It is now documented that thiazolidinediones, like
troglitazone, can lead to changes in gene expression
by speci¢cally binding to and activating PPARQ
[18,19,35]. While we have no evidence as to whether
troglitazone inhibits PEPCK gene expression via a
direct mechanism, the fact that the PEPCK promoter
has two PPAR response elements [36] makes this a
reasonable hypothesis. PPARQ has been shown to
transactivate the PEPCK promoter in non-liver cells
[36] ; the hypothesis we have developed suggests that
in liver cells, PPARQ, upon activation by troglita-
zone, inhibits the transcriptional activity of the
PEPCK promoter. Precisely how the same transcrip-
tion factor might confer opposite transcriptional re-
sponses in di¡erent tissues (i.e. up in adipose and
down in liver) is not immediately obvious, but it
may result from unique interactions of di¡erent ar-
rays of transcription factors which bind to the pro-
moter in select tissues. Indeed, di¡erential regulation
of the PEPCK gene in di¡erent cell types is not with-
out precedent; glucocorticoids inhibit PEPCK pro-
moter activity in adipocytes, but induce promoter
activity in liver cells [11]. It is also possible that tro-
glitazone indirectly inhibits PEPCK gene expression
through a mechanism, for example, whereby trogli-
tazone inhibits the expression of a transcription fac-
tor which is necessary for PEPCK gene activity in
liver. The issue of whether a direct or indirect mech-
anism is involved is currently being addressed by
examining which cis-element(s) in the PEPCK medi-
ates the troglitazone response. If a direct mechanism
is employed, then the troglitazone response should be
mediated through one or both of the PPAR response
elements.
It is also possible that troglitazone has intracellular
targets in addition to PPARQ that have not yet been
identi¢ed. The possibility of a second target is in fact
suggested by numerous studies showing that the bio-
chemical and/or physiological e¡ects of troglitazone
can be grouped into two general categories, based
upon whether they are observed at low or high con-
centrations of the drug. Many of these e¡ects, such
as stimulation of glucose uptake in adipocytes [37],
upregulation of LDL receptor activity in HepG2 cells
[38], stimulation of insulin release from isolated pan-
creatic islets [39], and inhibition of lipoprotein lipase
activity in adipocytes [40], are observed at low micro-
molar/high nanomolar concentrations, which is con-
sistent with the binding a⁄nity of troglitazone to
PPARQ [41]. However, there have been reported an-
other set of troglitazone e¡ects, including inhibition
of fatty acid oxidation and gluconeogenesis in hep-
atocytes [34,42] and attenuation of vascular contrac-
tility [43], which can only be observed at concentra-
tions ranging between 30 and 100 WM. Indeed, the
degree of inhibition of fatty acid oxidation and glu-
coneogenesis in hepatocytes increased as troglitazone
concentration was raised from 100 WM to 1 mM [34].
It is interesting to note that in hepatocytes, inhibition
of both gluconeogenesis [34] and expression of the
gene which codes for the rate-limiting enzyme of
this pathway (this article) require troglitazone con-
centrations in the higher range. Finally, it should be
noted that exposure of liver to concentrations ap-
proaching and indeed exceeding 100 WM is achiev-
able given the current recommended therapeutic dose
of troglitazone which ranges between 200 and 600
mg/day [44].
An interesting observation in the present study is
that troglitazone did not interfere with cAMP-indu-
cible expression of the PEPCK gene, another e¡ect
of this drug that distinguishes itself from that of in-
sulin. This suggests that under troglitazone-treated
conditions, the PEPCK gene remains competent for
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activation for those situations when gluconeogenesis
is required. This may explain one of the bene¢cial
characteristics of this drug as being able to lower
blood glucose without risk of hypoglycemia; at the
¢rst appearance of hypoglycemia, endogenous phys-
iological signals, such as glucagon secretion, would
lead to the activation of PEPCK gene expression and
allow enhancement of the gluconeogenic pathway.
In summary, we have uncovered two gene targets
for troglitazone which help further de¢ne the molec-
ular mechanisms whereby it reduces hepatic gluco-
neogenesis and thereby ameliorates hyperglycemia.
Since insulin and troglitazone appear to inhibit the
expression of both of these genes by di¡erent mech-
anisms, this study provides further support for pur-
suing clinical trials to examine the bene¢ts of com-
bined insulin and thiazolidinedione therapy.
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